The Effects of LAF237 on Gastric Function in Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- Registration Number
- NCT00952991
- Lead Sponsor
- Mayo Clinic
- Brief Summary
Administration of the incretin hormone, Glucagon-Like-Peptide-1 (GLP-1), has been shown to enhance insulin secretion and suppress glucagon secretion in response to meal ingestion. In addition, GLP-1 also delays gastric emptying and has been shown to enhance gastric accommodation. These characteristics make GLP-1 an ideal therapy for type 2 diabetes (T2D). However, because of its rapid breakdown by dipeptidylpeptidase IV (DPP IV), GLP-1 has to be administered by continuous intravenous infusion. This would be a drawback in clinical usage. LAF237 is a synthetic inhibitor of DPP IV which has been shown to raise GLP-1 levels and potentiate meal-induced insulin secretion and glucagon suppression. However, the effects of LAF237 on gastric emptying and satiety are at present unknown. The investigators propose to study the effects of LAF237 on gastric emptying, gastric volume and satiety in patients with T2D in addition to examining the direct and indirect (mediated via insulin and glucagon) of this compound on postprandial glucose metabolism.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 18
- Type 2 diabetes without microvascular or macrovascular complications treated with diet or up to 2 oral agents
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Gastric Emptying Gastric accommodation Satiety Gastrointestinal Symptoms
- Secondary Outcome Measures
Name Time Method Meal Appearance Rate Glucose Disappearance Endogenous Glucose Production Insulin Secretion Glucagon Secretion
Trial Locations
- Locations (1)
Mayo Clinic
🇺🇸Rochester, Minnesota, United States